How to trade Dr Reddy’s Labs shares after muted performance in Q1FY26? Know what analysts say

Dr Reddy's Labs Share Price Target: Dr Reddy's Laboratories, a multinational pharmaceutical company, on Wednesday, July 23, announced its financial performance for the first quarter of FY26.

The has posted a net profit at Rs 1,410, a one per cent increase in the June quarter.

The Hyderabad-based drug maker's revenue increased to Rs 8,545 crore during the period against Rs 7,673 crore YoY. After this development, what should investors do with the firm's stock? Analysts at global brokerages—Goldman Sachs, JPMorgan, Jefferies, CLSA, Morgan Stanley, Citi, and HSBC—have mixed stances after the pharma firm's earnings. Here is what they recommend:

Goldman Sachs has maintained a 'neutral' rating on Dr Reddy's Labs shares, raising share price target to Rs 1,200 from Rs 1,175.
 
JPMorgan has maintained an 'underweight' rating on the major pharma stock with a target of Rs 1,090, which raised from Rs 1,060. While Jefferies has maintained an 'underperform' stance on the stock, increasing the target price to Rs 1,100 from Rs 1,010.

(This story will be updates shortly.)